This multicenter, open-label, phase 3, single-arm study enrolled sexually active women aged 18–40 years at risk for pregnancy. Women received up to 1 year, or 13 consecutive 28-day cycles, of DSG 150 mcg/EE 20 mcg for 21 days and EE 10 mcg alone for 7 days. Participants kept diaries to record compliance, bleeding/spotting and other contraceptive use. Efficacy was measured using the Pearl Index (PI) and life-table approach. Safety and tolerability were assessed primarily through reported adverse events (AEs).
A total of 2858 women enrolled and 1680 completed the study. Forty-six pregnancies in 2401 women aged 18–35 years occurred after COC initiation and up to 7 days after last DSG/EE or EE-only tablet was taken. When cycles in which another contraceptive method was used were excluded, the PI was 2.68 [95% confidence interval (CI), 1.96–3.57]. The cumulative pregnancy rate after 1 year of treatment was 2.47% (95% CI, 1.85–3.29) for all users aged 18–35 years. When only cycles during which women considered compliant were included, the PI was 2.00 (95% CI, 1.39–2.80). AEs were similar to those seen with other oral contraceptives.
This 21/7-active DSG/EE COC with 7 days of low-dose EE was efficacious and well tolerated for pregnancy prevention.
This phase 3 open-label study demonstrated that a 21/7-active COC regimen including 21 days of DSG 150 mcg/EE 20 mcg and 7 days of EE 10 mcg was efficacious and well tolerated for pregnancy prevention.